8-K: Teleflex Reports Mixed Q4 Results but Provides Optimistic 2024 Guidance

Teleflex reported a slight revenue increase for Q4 2023, but a decrease in adjusted EPS, while providing a positive outlook for 2024 revenue and adjusted EPS growth.

Summary

• Teleflex announced its financial results for the fourth quarter and full year ended December 31, 2023.
• Fourth quarter revenues reached $773.9 million, a 2.1% increase year-over-year, but only a 0.7% increase on a constant currency basis, impacted by five fewer shipping days.
• GAAP diluted EPS from continuing operations was $0.66, down from $1.65 in the prior year period.
• Adjusted diluted EPS from continuing operations was $3.38, compared to $3.52 in the prior year period.
• Full year 2023 revenues were $2,974.5 million, a 6.6% increase year-over-year, or 6.5% on a constant currency basis.
• Full year GAAP diluted EPS from continuing operations was $7.56, compared to $7.67 in the prior year.
• Full year adjusted diluted EPS from continuing operations was $13.52, compared to $13.06 in the prior year.
• The company provided 2024 guidance with a GAAP revenue growth range of 3.60% to 4.60% and a constant currency revenue growth range of 3.75% to 4.75%.
• 2024 GAAP EPS from continuing operations is projected to be between $5.69 and $6.09, while adjusted diluted EPS is expected to be between $13.55 and $13.95.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the solid full-year results and optimistic 2024 guidance, although the Q4 adjusted EPS decrease and GAAP EPS decline temper the overall outlook.

Positives

• Full year revenue growth was strong at 6.6% year-over-year.
• The company achieved 6.5% constant currency revenue growth for the full year 2023.
• Teleflex expanded its geographic presence and launched new products in 2023.
• The company is progressing well with the integration of Palette Life Sciences.
• The company is committed to its corporate strategy for durable growth.
• The company is investing in both organic and inorganic growth drivers.
• The company's 2024 guidance indicates positive revenue and adjusted EPS growth.

Negatives

• Q4 2023 adjusted diluted EPS decreased by 4.0% year-over-year.
• Q4 2023 revenue growth was only 0.7% on a constant currency basis, impacted by five fewer shipping days.
• GAAP diluted EPS for Q4 2023 decreased significantly from $1.65 to $0.66 year-over-year.
• The company's GAAP EPS guidance for 2024 represents a decrease of 24.7% to 19.4%.

Risks

• The company's results are subject to fluctuations in foreign currency exchange rates.
• The company faces risks related to delays or cancellations in shipments.
• Demand for and market acceptance of new and existing products could impact results.
• The company's ability to integrate acquired businesses and realize synergies is a risk.
• The company's restructuring plans may not be executed effectively or achieve anticipated savings.
• Changes in healthcare reform legislation and reimbursement policies could affect the company.
• Competitive market conditions and increases in raw material costs could impact revenues and pricing.
• Global economic factors, including trade disputes and international conflicts, pose risks.
• Public health epidemics could impact the company's operations.

Future Outlook

Teleflex expects full year 2024 revenue growth of 3.60% to 4.60% on a GAAP basis and 3.75% to 4.75% on a constant currency basis. The company anticipates full year 2024 GAAP diluted earnings per share from continuing operations of $5.69 to $6.09 and adjusted diluted earnings per share from continuing operations of $13.55 to $13.95.

Management Comments

• Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer, stated that the company demonstrated solid execution during the fourth quarter against a stable to improving macro-environment.
• Mr. Kelly also noted that the company built upon its growth objectives, resulting in 6.5% constant currency revenue growth for 2023.
• Management is committed to the company's corporate strategy for durable growth.
• Management will continue to invest in organic and inorganic growth drivers.

Industry Context

The medical device industry is experiencing a period of growth, but also faces challenges related to regulatory changes, supply chain issues, and economic uncertainty. Teleflex's results and guidance reflect these trends, with a focus on growth through acquisitions and new product launches, while also managing costs and navigating a complex global environment.

Comparison to Industry Standards

• Teleflex's 6.5% constant currency revenue growth for 2023 is a solid result in the medical device industry, which has seen a range of growth rates depending on the specific sector and geographic focus.
• Companies like Medtronic and Abbott have reported similar growth rates in certain segments, while others have experienced slower growth or even declines.
• Teleflex's adjusted EPS growth of 3.5% for the full year is also within the range of what other large medical device companies have reported.
• The company's 2024 guidance for revenue and EPS growth is generally positive, but the projected decrease in GAAP EPS highlights the impact of non-recurring items and the importance of focusing on adjusted metrics.
• Compared to smaller, more specialized medical device companies, Teleflex's diversified portfolio provides a degree of stability and resilience, but may also limit its growth potential in specific high-growth areas.

Stakeholder Impact

• Shareholders will be impacted by the mixed Q4 results but positive 2024 guidance.
• Employees may be affected by ongoing restructuring and integration activities.
• Customers will benefit from new product launches and expanded geographic presence.
• Suppliers may see changes in demand due to the company's growth and restructuring.
• Creditors will be impacted by the company's financial performance and debt levels.

Next Steps

• Teleflex will continue to focus on its strategy to drive durable growth.
• The company will progress with the integration of Palette Life Sciences.
• Teleflex will continue to invest in organic and inorganic growth drivers.
• The company will hold a conference call to discuss the financial results on February 22, 2024.

Key Dates

Keywords

Teleflex, medical devices, financial results, revenue, EPS, constant currency, growth, acquisition, guidance, healthcare